ECM1: A Potential Drug Target and Biomarker (G1893)

Target Name: ECM1

NCBI ID: G1893

ECM1

ECM1: A Potential Drug Target and Biomarker

ECM1, also known as ECM-1A, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the ECM family, which is known for their role in the formation of extracellular matrix (ECM) in various organisms. ECM1 has been identified as a potential drug target and biomarker due to its unique structure, expression, and function.

Structure and Expression

ECM1 is a transmembrane protein that consists of two distinct domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain is responsible for the protein's ability to interact with various cell signaling pathways, including the TGF-β pathway. The C-terminal domain is involved in the protein's ability to interact with the ECM, including the extracellular matrix (ECM) in various organisms.

ECM1 is expressed in various tissues of the body, including the brain, heart, and kidneys. It is highly expressed in the brain, where it is found in the glial cells, which are responsible for maintaining the structure and function of the nervous system. ECM1 is also expressed in the heart and kidneys, where it is involved in the formation of the cardiac intercellular matrix and the glomerular filtration membrane.

Function

ECM1 plays a crucial role in the formation of the ECM in various organisms. The ECM is a complex structure that is composed of various proteins that help to maintain the extracellular environment, including the cytoskeleton, adhesion molecules, and signaling proteins. ECM1 is involved in the formation of the ECM by helping to regulate the activity of other ECM proteins, including the cytoskeleton.

ECM1 is also involved in the regulation of various cellular processes in the body, including cell signaling, cell division, and cell survival. It is a negative regulator of the TGF-β pathway, which is a well-known signaling pathway that is involved in the regulation of cellular processes, including cell growth, differentiation, and survival.

Drug Target Potential

ECM1 is a potential drug target due to its involvement in the TGF-β pathway and its role in the regulation of cellular processes. Drugs that target ECM1 have the potential to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One approach to targeting ECM1 is to use small molecules that can inhibit the activity of ECM1. Such drugs have been shown to have a variety of therapeutic effects, including the inhibition of cancer cell growth, the treatment of neurodegenerative diseases, and the regulation of autoimmune diseases.

Biomarker Potential

ECM1 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its involvement in the TGF-β pathway and its ability to regulate cellular processes make it an attractive candidate for the development of diagnostic tests for these diseases.

ECM1 has been shown to be involved in the regulation of various cellular processes, including cell signaling, cell division, and cell survival. Its expression is highly correlated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Conclusion

ECM1 is a protein that is involved in the formation of the extracellular matrix and has been identified as a potential drug target and biomarker. Its unique structure and expression, as well as its involvement in the TGF-β pathway and its role in the regulation of cellular processes make it an attractive candidate for the development of new therapeutic drugs. Further research is needed to fully understand the function and potential of ECM1 in various organisms.

Protein Name: Extracellular Matrix Protein 1

Functions: Involved in endochondral bone formation as negative regulator of bone mineralization. Stimulates the proliferation of endothelial cells and promotes angiogenesis. Inhibits MMP9 proteolytic activity

The "ECM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ECM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets